NCT01578239 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 117
- group Id
- BG001
- value
- 114
- group Id
- BG002
- value
- 231
- units
- Participants
- groups
- description
- * 30 mg Octreotide LAR treatment for symptom control continued until the end of study, unless the participant progressed or died. * Treatment consisted of a cumulative administered radioactivity of 29.6 Giga Becquerel (GBq) (800 mCi) 177Lu-DOTA0-Tyr3-Octreotate: Four administrations of 7.4 GBq (200 mCi). * Concomitant amino acids were given with each administration for kidney protection. * 177Lu-DOTA0-Tyr3-Octreotate was administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity. * In case participants experienced clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, Octreotide s.c. rescue injections were allowed.
- id
- BG000
- title
- 177Lu-DOTA0-Tyr3-Octreotate
- description
- * 60 mg Octreotide LAR treatment every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died. * In case participants experienced clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, s.c. Octreotide rescue injections were allowed.
- id
- BG001
- title
- Octreotide LAR
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 9.34
- value
- 63.4
- group Id
- BG001
- spread
- 9.80
- value
- 64.0
- group Id
- BG002
- spread
- 9.55
- value
- 63.7
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 54
- group Id
- BG001
- value
- 60
- group Id
- BG002
- value
- 114
- title
- Female
- measurements
- group Id
- BG000
- value
- 63
- group Id
- BG001
- value
- 54
- group Id
- BG002
- value
- 117
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 10
- title
- Black or African American
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 9
- title
- Hispanic
- categories
- measurements
- group Id
- BG000
- value
- 93
- group Id
- BG001
- value
- 96
- group Id
- BG002
- value
- 189
- title
- White
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- Other
- categories
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 21
- title
- Not Applicable
- param Type
- NUMBER
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 117
- group Id
- BG001
- value
- 114
- group Id
- BG002
- value
- 231
- units
- Participants
- groups
- description
- * 30 mg Octreotide LAR treatment for symptom control continued until the end of study, unless the participant progressed or died. * Treatment consisted of a cumulative administered radioactivity of 29.6 Giga Becquerel (GBq) (800 mCi) 177Lu-DOTA0-Tyr3-Octreotate: Four administrations of 7.4 GBq (200 mCi). * Concomitant amino acids were given with each administration for kidney protection. * 177Lu-DOTA0-Tyr3-Octreotate was administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity. * In case participants experienced clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, Octreotide s.c. rescue injections were allowed.
- id
- BG000
- title
- 177Lu-DOTA0-Tyr3-Octreotate
- description
- * 60 mg Octreotide LAR treatment every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died. * In case participants experienced clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, s.c. Octreotide rescue injections were allowed.
- id
- BG001
- title
- Octreotide LAR
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 9.34
- value
- 63.4
- group Id
- BG001
- spread
- 9.80
- value
- 64.0
- group Id
- BG002
- spread
- 9.55
- value
- 63.7
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 54
- group Id
- BG001
- value
- 60
- group Id
- BG002
- value
- 114
- title
- Female
- measurements
- group Id
- BG000
- value
- 63
- group Id
- BG001
- value
- 54
- group Id
- BG002
- value
- 117
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 10
- title
- Black or African American
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 9
- title
- Hispanic
- categories
- measurements
- group Id
- BG000
- value
- 93
- group Id
- BG001
- value
- 96
- group Id
- BG002
- value
- 189
- title
- White
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- Other
- categories
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 21
- title
- Not Applicable
- param Type
- NUMBER
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle